Stock Analysis
Celcuity Inc. (CELC) Stock Analysis
Celcuity Inc. (CELC) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Celcuity Inc. (CELC) currently has an AIQ Score of 41/100, indicating a bearish setup. Quality is the strongest factor at 63/100. Momentum is the weakest current factor at 24/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
CELC at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $64.37 |
| AIQ Score | 41/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $3.55B |
| P/E Ratio (TTM) | -13.7 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$1.33 |
| Revenue (Q3 FY2026) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.12 |
| Volume | 646.5K |
| 52-week range | $53.54-$151.02 |
| RSI 14 | 43.22 |
| 50-Day SMA | $72.47 |
| 200-Day SMA | $98.45 |
| Analyst Price Target | $158.50 |
| Next Earnings | — |
CELCCelcuity Inc.
Healthcare / Biotechnology
Low Priority
Above Peers
Latest quote
- Momentum24
- Value—
- Quality63
- Risk resilience34
- Sentiment—
CELC Stock Analysis Summary
Celcuity Inc. (CELC) currently has an AIQ Score of 41/100, indicating a bearish setup. Quality is the strongest factor at 63/100. Momentum is the weakest current factor at 24/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, CELC has AIQ Score of 41/100 with Quality base of 63/100 and fading Momentum at 24/100. Wait for component alignment before adding exposure.
Quality (63/100) leads while Momentum (24/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 0.31% stock move · CELC classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is CELC Bullish or Bearish Right Now?
CELC currently has a bearish overall setup. Quality is the strongest factor at 63/100, while Momentum is weakest at 24/100. The current evidence suggests a bearish setup.
- - Analyst target implies +146.23% upside from the latest quote.
- - Momentum is weak at 24/100.
- - Risk Resilience is weak at 34/100.
- - Price is -34.62% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (32 vs 6).
Current Consensus
CELC's Technical Analysis Consensus is currently Strong Sell, with 6 buy, 8 neutral, and 32 sell votes. CELC's 14-day RSI is 43.22, which places the stock in a weaker momentum range. CELC's beta is 1.12, indicating market sensitivity broadly in line with the market.
What Changed in CELC?
The largest recent change in CELC is Momentum moving down by 2.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the CELC Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
CELC Decision Framework
Public evidence layers, setup checks, and risk context for Celcuity Inc..
Celcuity Inc. (CELC) Stock Analysis
Celcuity Inc. has an AIQ Score of 41/100 in a Bearish regime. Quality is strongest at 63/100. Beta is 1.12, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | CELC is in a Bearish AIQ regime with score 41/100. |
| Signal Conflict | The primary conflict is that quality leads at 63/100 while momentum lags at 24/100. |
| Factor Evidence | Momentum 24/100 · Quality 63/100 · Risk 34/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 63/100.
Momentum is 24/100 and RSI (14) is 43.2.
CELC is in a Bearish regime at 41/100.
Risk factor is 34/100 with beta 1.12 and annual volatility 63.58%.
Current conflict: quality leads at 63/100 while momentum lags at 24/100.
CELC Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
CELC Fundamentals
CELC valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
CELC Technical Analysis
CELC technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
CELC Stock Catalysts
Track CELC earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
CELC Dividend Analysis
CELC dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
CELC Financial Data
CELC revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
CELC Risk Analysis
CELC volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
CELC Stock News
CELC stock news, market tone, recent headlines, and catalyst context.
CELC vs Biotechnology Peers
Current peer cohort: CELC · CGON · CLDX · COGT · CYTK. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| CELC Current stock | 41/100 | — | 24/100 | 34/100 | -0.19 | 63.58% | Current |
| CGON CG Oncology Inc. | 59/100 | — | 71/100 | 59/100 | 1.38 | 58.41% | CELC vs CGON |
| CLDX Celldex Therapeutics, Inc. | 43/100 | — | 48/100 | 55/100 | 0.55 | 52.44% | CELC vs CLDX |
| COGT Cogent Biosciences, Inc. | 44/100 | — | 45/100 | 51/100 | -0.23 | 45.96% | CELC vs COGT |
| CYTK Cytokinetics, Incorporated | 40/100 | 41/100 | 28/100 | 56/100 | -0.23 | 43.65% | CELC vs CYTK |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for CELC: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching CELC
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for CELC
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
CELC Stock FAQ
What is CELC stock price today?
Celcuity Inc.'s current stock price is $64.37. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is CELC bullish or bearish right now?
CELC's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is CELC's market cap?
CELC's market cap is $3.55B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is CELC's current P/E ratio?
CELC's current P/E ratio is -13.7 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is CELC's RSI?
CELC's 14-day RSI is 43.22 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is CELC above its 50-day and 200-day moving averages?
CELC is -11.18% from its 50-day SMA and -34.62% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is CELC's next earnings date?
CELC's next earnings date is a key event to check before making a decision. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does CELC pay a dividend?
CELC's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.